Jérémie Thereaux1,2, Fanny Mingant3,4, Charles Roche5, Hubert Galinat3,4, Francis Couturaud3,6,7, Karine Lacut3,6,7. 1. Department of General, Digestive and Metabolic Surgery, La Cavale Blanche University Hospital, Boulevard Tanguy Prigent, 29200, Brest, France. jeremie.thereaux@chu-brest.fr. 2. University of Bretagne Occidentale (UBO), EA 3878 (GETBO), 22 Avenue Camille Desmoulins, CS 93837-29238, Brest, France. jeremie.thereaux@chu-brest.fr. 3. University of Bretagne Occidentale (UBO), EA 3878 (GETBO), 22 Avenue Camille Desmoulins, CS 93837-29238, Brest, France. 4. Laboratory of Hemostasis, La Cavale Blanche University Hospital, Boulevard Tanguy Prigent, 29200, Brest, France. 5. Department of General, Digestive and Metabolic Surgery, La Cavale Blanche University Hospital, Boulevard Tanguy Prigent, 29200, Brest, France. 6. Department of Internal Medicine, La Cavale Blanche University Hospital, Boulevard Tanguy Prigent, 29200, Brest, France. 7. INSERM, CIC1412, La Cavale Blanche University Hospital, Boulevard Tanguy Prigent, 29200, Brest, France.
Abstract
PURPOSE: Obese patients are known to be in an in vitro hypercoagulable state relative to normal-weight patients. Our study aimed to identify markers of enhanced coagulability (endogenous thrombin potential (ETP)) in morbidly obese patients using the thrombin generation (TG) test. MATERIALS AND METHODS: All patients scheduled for laparoscopic bariatric surgery (LBS) between September 1, 2014 and January 31, 2016 were eligible for our prospective study. We used logistic regression to compute the odds ratio (OR) across ETP quartile distributions to evaluate the risk of enhanced TG. RESULTS: We studied 102 patients, 77.5% were female, mean age was 41.2 ± 12.1 years, and mean BMI was 45.5 ± 7.0 k/m2. Total cholesterol and fibrinogen levels were found to be independent risk factors for patients in the 4th quartile distribution of the ETP distribution (OR (95% CI)) 2.6 (1.2 to 5.4) (P = 0.01) and 2.2 (1.1 to 4.5 (P = 0.03). Patients in the 4th quartile of the ETP distribution had a lower ETP 1 month after surgery (157 (144-196) vs. 120 (98-140); P < 0.001) in parallel with a trend toward lower total cholesterol levels (5.0 ± 0.9 vs. 4.4 ± 1.0; P = 0.06). Fibrinogen levels were stable (4.5 ± 1.0 vs. 4.4 ± 0.9); P = 0.7). CONCLUSIONS: Our study highlights the role of total cholesterol and blood inflammatory marker levels in enhancing ETP in morbidly obese patients. Further studies are necessary to confirm the decreased ETP following LBS with the expected reduced inflammatory marker and total cholesterol levels.
PURPOSE:Obesepatients are known to be in an in vitro hypercoagulable state relative to normal-weight patients. Our study aimed to identify markers of enhanced coagulability (endogenous thrombin potential (ETP)) in morbidly obesepatients using the thrombin generation (TG) test. MATERIALS AND METHODS: All patients scheduled for laparoscopic bariatric surgery (LBS) between September 1, 2014 and January 31, 2016 were eligible for our prospective study. We used logistic regression to compute the odds ratio (OR) across ETP quartile distributions to evaluate the risk of enhanced TG. RESULTS: We studied 102 patients, 77.5% were female, mean age was 41.2 ± 12.1 years, and mean BMI was 45.5 ± 7.0 k/m2. Total cholesterol and fibrinogen levels were found to be independent risk factors for patients in the 4th quartile distribution of the ETP distribution (OR (95% CI)) 2.6 (1.2 to 5.4) (P = 0.01) and 2.2 (1.1 to 4.5 (P = 0.03). Patients in the 4th quartile of the ETP distribution had a lower ETP 1 month after surgery (157 (144-196) vs. 120 (98-140); P < 0.001) in parallel with a trend toward lower total cholesterol levels (5.0 ± 0.9 vs. 4.4 ± 1.0; P = 0.06). Fibrinogen levels were stable (4.5 ± 1.0 vs. 4.4 ± 0.9); P = 0.7). CONCLUSIONS: Our study highlights the role of total cholesterol and blood inflammatory marker levels in enhancing ETP in morbidly obesepatients. Further studies are necessary to confirm the decreased ETP following LBS with the expected reduced inflammatory marker and total cholesterol levels.
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand Journal: Lancet Date: 2005-11-05 Impact factor: 79.321
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Hanneke J B H Beijers; Isabel Ferreira; Henri M H Spronk; Bert Bravenboer; Jacqueline M Dekker; Giel Nijpels; Hugo ten Cate; Coen D A Stehouwer Journal: Arterioscler Thromb Vasc Biol Date: 2010-09-16 Impact factor: 8.311
Authors: Elena Campello; Luca Spiezia; Eva Zabeo; Sara Maggiolo; Roberto Vettor; Paolo Simioni Journal: Thromb Res Date: 2015-01-07 Impact factor: 3.944
Authors: D Wayne Overby; Geoffrey P Kohn; Mitchell A Cahan; Joseph A Galanko; Karen Colton; Stephan Moll; Timothy M Farrell Journal: Obes Surg Date: 2009-07-05 Impact factor: 4.129
Authors: Ibrahim AlZaim; Aya Al-Saidi; Safaa H Hammoud; Nadine Darwiche; Yusra Al-Dhaheri; Ali H Eid; Ahmed F El-Yazbi Journal: Cancers (Basel) Date: 2022-03-25 Impact factor: 6.639